Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase II Study of Systemic Therapy With Combined Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR) in Pancreatic Cancer

NCT07269626 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT07269626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07269626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase II Study of Systemic Therapy With Combined Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR) in Pancreatic Cancer
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
November 14, 2025
Completion date
December 31, 2028
Enrollment
47 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

borderline resectable pancreatic ductal adenocarcinoma, locally advanced pancreatic ductal adenocarcinoma, oligometastatic pancreatic ductal adenocarcinoma